HUTCHMED (China) Limited (HCM) P/E Ratio History
ExpensiveTrading at 148.0x vs 5Y avg 81.1x · 86th percentile · Material premium to history · Data 2016–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, HUTCHMED (China) Limited (HCM) trades at a price-to-earnings ratio of 148.0x, with a stock price of $15.16 and trailing twelve-month earnings per share of $0.10.
The current P/E is 82% above its 5-year average of 81.1x. Over the past five years, HCM's P/E has ranged from a low of 5.1x to a high of 219.9x, placing the current valuation at the 86th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, HCM trades at a 502% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, HCM commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HCM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HCM Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
HCM P/E vs Peers
Commercial Oncology Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $515B | 49.9 | - | -1% | |
| $362B | 148.2 | 6.98 | +8% | |
| $127B | 13.8Lowest | - | +178% | |
| $17B | 20.1 | 0.39Best | +58% | |
| $24B | 60.3 | - | +4173%Best | |
| $291B | 26.5 | 1.21 | +45% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
HCM Historical P/E Data (2016–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $10.76 | $0.10 | 104.5x | +29% |
| FY2026 Q1 | - | $14.96 | $1.36 | 11.0x | -86% |
| FY2025 Q4 | Dec 31 2025 | $13.33 | $2.61 | 5.1x | -94% |
| FY2025 Q3 | - | $15.75 | $2.65 | 5.9x | -93% |
| FY2025 Q2 | Jun 30 2025 | $15.05 | $2.69 | 5.6x | -93% |
| FY2025 Q1 | Mar 31 2025 | $15.04 | $1.46 | 10.3x | -87% |
| FY2024 Q4 | - | $14.41 | $0.23 | 61.6x | -24% |
| FY2024 Q1 | Mar 31 2024 | $16.80 | $0.16 | 102.4x | +26% |
| FY2023 Q4 | Dec 31 2023 | $18.11 | $0.58 | 31.2x | -62% |
| FY2023 Q3 | Sep 30 2023 | $16.94 | $0.18 | 94.1x | +16% |
| FY2017 Q2 | Jun 30 2017 | $23.31 | $0.11 | 219.9x | +171% |
| FY2017 Q1 | Mar 31 2017 | $19.95 | $0.10 | 196.6x | +142% |
| FY2016 Q4 | Dec 31 2016 | $13.57 | $0.10 | 139.9x | +72% |
| FY2016 Q3 | Sep 30 2016 | $11.90 | $0.08 | 147.8x | +82% |
Average P/E for displayed period: 81.1x
HCM Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HCM — Frequently Asked Questions
Quick answers to the most common questions about buying HCM stock.
What is HCM's P/E ratio?
HUTCHMED (China) Limited (HCM) trailing twelve-month P/E ratio is 148.0x, based on TTM diluted EPS of $0.10. The 5-year average P/E is 81.1x and the historical range spans 5.1x to 219.9x.
Is HCM stock overvalued or undervalued?
HCM trades at 148.0x P/E, above its 5-year average of 81.1x. The 86th percentile ranking within the 5.1x–219.9x historical range indicates a premium to historical valuation.
Is HCM stock expensive?
Yes, HCM is expensive relative to its own history. The current P/E of 148.0x is above the 5-year average of 81.1x and also above the Healthcare sector median of 24.6x. The stock sits at the 86th percentile of its 5-year valuation range.
What is HCM's historical P/E range?
Over the past 5 years, HCM's P/E ratio has ranged from 5.1x to 219.9x, with a median of 94.1x and an average of 81.1x. The current P/E of 148.0x places the stock at the 86th percentile of this range. Full historical data spans 2016–2026.
How does HCM's P/E compare to the S&P 500?
HCM trades at 148.0x P/E versus the S&P 500 median of 21.8x. The 579% premium to the market typically reflects higher expected earnings growth or quality.
How does HCM's valuation compare to Healthcare peers?
HUTCHMED (China) Limited P/E of 148.0x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is HCM's PEG ratio?
HCM PEG ratio is N/A, based on a P/E of 148.0x and EPS growth of 1081.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is HCM's earnings yield?
HCM earnings yield is 0.68%, the inverse of its 148.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.